Letter to the Editor: Enhancing renin-angiotensin-aldosterone system inhibitors utilization through patiromer adherence - real-world insights for nephrology practice

doi:10.5527/wjn.119286

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

(0)

(1)

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Sep 25, 2026; 15(3): 119286
Published online Sep 25, 2026. doi: 10.5527/wjn.119286

Table 1 Renin-angiotensin-aldosterone system inhibitors utilization by patiromer adherence

RAASi class	Adherent days supply (95%CI)	Lower days supply (95%CI)	Difference (P value)	Adherent PDC (%)	Lower PDC (%)	≥ 80% PDC (adherent vs lower) (%)
ACEi	122.8 (120.0-125.6)	111.2 (109.4-113.1)	11.6 (P < 0.0001)	88.8	84.2	79.2 vs 70.7
ARB	121.2 (118.2-124.3)	111.8 (110.0-113.7)	9.4 (P < 0.0001)	90.9	85.5	77.5 vs 71.5
MRA	114.5 (108.1-121.0)	105.0 (101.2-108.7)	9.6 (P = 0.0122)	87.2	79.1	72.1 vs 62.3

PDC: Proportion of days covered; CI: Confidence interval; ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; MRA: Mineralocorticoid receptor antagonist; RAASi: Renin-angiotensin-aldosterone system inhibitors.

Full Size Table

Citation: Feyissa GD. Letter to the Editor: Enhancing renin-angiotensin-aldosterone system inhibitors utilization through patiromer adherence - real-world insights for nephrology practice. World J Nephrol 2026; 15(3): 119286
URL: https://www.wjgnet.com/2220-6124/full/v15/i3/119286.htm
DOI: https://dx.doi.org/10.5527/wjn.119286

Feyissa GD. Letter to the Editor: Enhancing renin-angiotensin-aldosterone system inhibitors utilization through patiromer adherence - real-world insights for nephrology practice. World J Nephrol 2026; 15(3): 119286 [DOI: 10.5527/wjn.119286]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.